Name | No. | For Patients with | Purpose |
---|---|---|---|
SHAMROCK study | 22-01 | Patient with newly diagnosed early stage HER2-positive breast cancer with tumour size larger than 2cm |
The goal of this study is to investigate how effective neoadjuvant treatment with trastuzumab deruxtecan is for patients with early stage locally advanced HER2 positive breast cancer. |
DSSG Group: Breast
EPIK-B5
Name | No. | For Patients with | Purpose |
---|---|---|---|
EPIK-B5 | 21-32 | HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor. |
The purpose of this study is to obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in men or postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor. |
KEYNOTE-B49
Name | No. | For Patients with | Purpose |
---|---|---|---|
KEYNOTE-B49 | 21-31 | Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer |
To assess the safety and efficacy of pembrolizumab plus the investigator’s choice of chemotherapy compared to placebo plus the investigator’s choice of chemotherapy |
SASCIA
Name | No. | For Patients with | Purpose |
---|---|---|---|
SASCIA | 20-24 | Primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment |
This study is a phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA |
Proteomics / Molecular Breast
Name | No. | For Patients with | Purpose |
---|---|---|---|
Proteomics / Molecular Breast | 09-07 | Breast cancer |
The purpose of this trial is to examine the function of different genes and proteins, previously identified to be of interest, and identify new ones, as well as the means by which they interact and differ between cancer cells. |